Safety and efficacy of atezolizumab with rituximab and CHOP in previously untreated diffuse large B-cell lymphoma

Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is the current standard therapy for patients with diffuse large B-cell lymphoma (DLBCL) and is curative in ∼60% of patients. Atezolizumab is a humanized immunoglobulin G1 monoclonal antibody that targets programmed de...

Descripción completa

Detalles Bibliográficos
Autores principales: Younes, Anas, Burke, John M., Cheson, Bruce D., Diefenbach, Catherine S., Ferrari, Silvia, Hahn, Uwe H., Hawkes, Eliza A., Khan, Cyrus, Lossos, Izidore S., Musuraca, Gerardo, Tani, Monica, Vitolo, Umberto, Yuen, Sam, Raval, Aparna, Shivhare, Mahesh, Nielsen, Tina G., Sellam, Gila, Sharman, Jeff P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10125909/
https://www.ncbi.nlm.nih.gov/pubmed/36287231
http://dx.doi.org/10.1182/bloodadvances.2022008344

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10125909/
https://www.ncbi.nlm.nih.gov/pubmed/36287231
http://dx.doi.org/10.1182/bloodadvances.2022008344

Ejemplares similares